Proactive Investors - Run By Investors For Investors

Scancell hires two industry veterans as it gears up for the next development phase

The company has brought in outside research and manufacturing expertise
pictured are T-cells attacking a cancer cell
Dr Samantha Paston is a T-cell cloning expert (pictured are T-cells attacking a cancer cell)

Scancell Holdings PLC (LON:SCLP) has made two experienced hires as it gears up for its next phase of development.

T-cell cloning specialist Dr Samantha Paston is the company’s new head of research, while Dr Adrian Parry will take charge of manufacturing.

Paston arrived in mid-January from Oxford-based biotech unicorn Immunocore, where she made “significant contributions” to the company’s current oncology pipeline.

Before joining Immunocore, she held roles at Medigene, Avidex, NIBSC and GlaxoSmithKline. She gained her PhD at University College London.

Parry joins Scancell on February 1 from Mereo BioPharma, where he was head of small molecule chemistry, manufacturing and controls).

He has over two decades’ experience delivering “multiple, complex” drug products.

“We are delighted to welcome both Samantha and Adrian to Scancell,” said chief executive Cliff Holloway.

“Samantha’s experience in T-cell cloning and working with biological molecules, from drug discovery through to early development, will be invaluable as we continue to progress our pipeline of cancer immunotherapies.

“Likewise, Adrian’s 20 years of CMC and GMP development expertise will be key for our manufacturing capabilities moving forward.”

AIM-listed Scancell is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise – they are the ImmunoBody and Moditope platforms.

The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

The UK group is planning to use SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
bacteria
December 17 2018
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use